Compare JOE & SYRE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | JOE | SYRE |
|---|---|---|
| Founded | 1936 | 2013 |
| Country | United States | United States |
| Employees | N/A | 102 |
| Industry | Homebuilding | Biotechnology: Pharmaceutical Preparations |
| Sector | Real Estate | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 3.7B | 4.0B |
| IPO Year | 2002 | 2015 |
| Metric | JOE | SYRE |
|---|---|---|
| Price | $67.20 | $51.91 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 8 |
| Target Price | N/A | ★ $60.13 |
| AVG Volume (30 Days) | 222.2K | ★ 730.9K |
| Earning Date | 04-22-2026 | 05-07-2026 |
| Dividend Yield | ★ 0.94% | N/A |
| EPS Growth | ★ 56.69 | N/A |
| EPS | ★ 1.99 | N/A |
| Revenue | ★ $513,246,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $34.13 | ★ N/A |
| Revenue Growth | ★ 27.44 | N/A |
| 52 Week Low | $40.46 | $12.04 |
| 52 Week High | $73.54 | $54.39 |
| Indicator | JOE | SYRE |
|---|---|---|
| Relative Strength Index (RSI) | 53.71 | 67.75 |
| Support Level | $66.26 | $39.64 |
| Resistance Level | $72.67 | N/A |
| Average True Range (ATR) | 1.73 | 2.77 |
| MACD | 0.56 | 0.41 |
| Stochastic Oscillator | 83.71 | 80.42 |
The St. Joe Co is a real estate development, asset management, and operating company and it has three operating segments; the Residential segment plans and develops residential communities and sells homesites to homebuilders or retail consumers, the Hospitality segment that derives maximum revenue, features a private membership club, hotel operations, food and beverage operations, golf courses, beach clubs, retail outlets, gulf-front vacation rentals, management services, marinas, and other entertainment assets, and Commercial segment include leasing of commercial property, multi-family, senior living, self-storage, and other assets and it also oversees the planning, development, entitlement, management, and sale of commercial and rural land holdings.
Spyre Therapeutics Inc is a clinical-stage biotechnology company pioneering long-acting antibodies and antibody combinations to redefine the standard of care for inflammatory bowel disease (IBD) and rheumatic diseases. Spyre's pipeline includes extended half-life antibodies targeting α4β7, TL1A, and IL-23 in development as monotherapies and pair-wise combinations. It has a single reportable segment, which is the development of biopharmaceutical products for the treatment of patients with IBD and other immune-mediated disease.